U nlike the explosive hyperplastic growth that occurs during early embryonic development, neonatal and adult cardiomyocytes undergo hypertrophy as a consequence of a much more subtle increase in the fractional growth rate of the heart. Both physiological and pathological hypertrophy results from mechanical and neurohormonal signals (and their downstream effectors) that tend to increase the rate of cardiac protein synthesis. These growth-promoting pathways are counterbalanced by signaling molecules that tend to inhibit or attenuate the prohypertrophic growth response. 1 In this issue of Circulation Research, Jeong et al 2 continue to add to a growing list of negative regulators of cardiomyocyte hypertrophy, and describe how PICOT (protein kinase C-interacting cousin of thioredoxin) may function to inhibit the calcineurin (CnA)nuclear factor of activated T cells (NFAT) signaling pathway responsible for regulating specific aspects of the hypertrophic phenotype.
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PICOT Is a Multidomain Scaffolding
Inhibitor of Protein Kinase C-PICOT was first identified in 2000 by Witte et al in a yeast 2-hybrid screen of protein kinase C (PKC)-interacting proteins. 3 These authors used full-length, catalytically inactive PKC to screen a Jurkat T-cell lymphoma cDNA library. They identified a highly conserved, 37.5-kDa cytoplasmic protein containing at least 2 functional domains. The N-terminal, PKC binding domain shared sequence homology with the thioredoxin family of proteins but lacked the conserved Cys-Gly-Pro-Cys motif essential for enzyme activity. The C-terminal domain contained 2 tandem repeats, now called PICOT homology (PIH) domains that are shared by proteins expressed in a diverse group of organisms. PICOT formed a protein complex with PKC (but not PKC␣) in vitro and in living cells and inhibited the PKC-induced activation of c-Jun N-terminal kinases but not extracellular signal-regulated kinases. This inhibitory effect was also partially dependent on CnA overexpression, suggesting an interaction among PKC, PICOT, and CnA in their model system. In a subsequent report, Jeong et al 4 examined the potential role of PICOT as a regulator of cardiac hypertrophy.
They showed that endogenous PICOT expression increased 2-fold in the cardiomyocytes of mice subjected to transverse aortic coarctation. PICOT upregulation also occurred in cultured neonatal cardiomyocytes in response to the hypertrophic agonists phenylephrine and endothelin-1. Furthermore, transgenic overexpression of PICOT abrogated pressure overload-induced cardiac hypertrophy in vivo. Although these observations, as well as an accompanying editorial, 5 focused on the potential inhibitory effects of PICOT on cardiomyocyte PKCs, it remained unclear exactly what signaling pathways were involved. One obvious issue with the PKC dependence of the antihypertrophic effect of PICOT was the fact that mouse cardiomyocytes do not express PKC; therefore, the antihypertrophic effects of PICOT likely involved other mechanisms.
PICOT-Muscle LIM Protein-CnA Interactions in Cardiomyocytes
Jeong et al 2 (Figure) . Finally, the authors extend their previous observations 4 by demonstrating that PICOT overexpression enhanced myofibrillar organization in neonatal cardiomyocytes and increased the velocity of fiber shortening when overexpressed in adult cells.
PICOT, MLP, and Mechanotransduction
These elegant studies have important implications and substantially advance our understanding of hypertrophic signal transduction. A key element is the interaction between PICOT and MLP. MLP belongs to a family of cysteine-rich proteins that are involved in protein-protein interactions within the cytoplasm, as well as the nucleus. MLP specifi-cally interacts with several other proteins within the Z-disc, including ␣-actinin, zyxin, T-cap/telethonin, and CnA (reviewed elsewhere 6 ). Mice with targeted ablation of the MLP gene develop dilated cardiomyopathy, 7 whereas point mutations in MLP are known to cause either hypertrophic or dilated cardiomyopathy in humans. [7] [8] [9] In addition to its structural role, MLP is critically involved in stretch-induced activation of brain natriuretic peptide transcription, 7 and recent studies suggest that MLP may shuttle between the Z-disc and the nucleus in response to mechanical stress. 10 Thus, their observation that PICOT inhibits MLP-CnA-NFAT signaling provides a previously unrecognized node at which signals arising from adrenergic receptors, altered calcium cycling, and mechanotransduction merge. The authors did not, however, examine whether PICOT binding to MLP at the Z-disc prevented its nuclear translocation in response mechanical stimuli that cause hypertrophy. However, cytoskeletal-nuclear shuttling of proteins with dual structural and signaling functions may be a much more common mechanism of signal transmission than previously appreciated. [11] [12] [13] A more detailed analysis of the structural domains of PICOT involved in competitive binding of MLP and CnA seems warranted.
Unanswered Questions
Despite these carefully performed studies, a number of questions regarding the function of PICOT in cardiomyocyte signaling remain unanswered. First, what, if any, is the role of PICOT in modulating PKC activity in cardiomyocytes? Witte et al 3 originally showed that PICOT binds PKC, a novel, Ca 2ϩ -independent PKC. However, novel (n)PKC and nPKC␦ are the major nPKC isoenzymes expressed in cardiomyocytes; therefore, it remains to be determined whether these isoforms are also inhibited by PICOT overexpression. This is an important issue, because the agonists used to elicit hypertrophy in the studies by Jeong and colleagues 2,4 are also potent activators of nPKCs in neonatal and adult cardiomyo-cytes. 14 15 but other mechanisms may be involved. However, it seems counterintuitive that a molecule that inhibits CnA-dependent signaling and prevents phenylephrine-induced, neonatal cardiomyocyte sarcomeric organization can also increase shortening velocity in adult cardiomyocytes. This dichotomy of structure and function in cardiomyocyte hypertrophy awaits future investigation. 
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Figure.
Crossroads of signal transduction at the Z-disc. As described in this issue of Circulation Research, 2 overexpression of PICOT, as occurs during pressure overload-induced cardiac hypertrophy, negatively regulates hypertrophic signal transduction by binding to MLP at the Z-disc. PICOT competitively displaces CnA binding to MLP, thus disrupting downstream signaling and dephosphorylation of NFAT. PICOT may also bind to nPKC isoenzymes and inhibit their downstream signaling to the mitogen-activated protein kinases (MAPKs) and other signaling pathways.
